Bionano Genomics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Benzinga Earnings

03/20

Bionano Genomics, Inc. (NASDAQ:BNGO) will release earnings results for its fourth quarter, after the closing bell on Monday, March 23.

Analysts expect the San Diego, California-based company to report a quarterly loss at $1.40 per share on revenue of $7.85 million, according to data from Benzinga Pro.

On Jan. 12, Bionano Genomics said it expects fourth-quarter revenue of $7.8 million-$8.0 million and FY25 total revenue of $28.4 million-$28.6 million.

Bionano Genomics shares closed at $1.12 on Thursday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.

HC Wainwright & Co. analyst Yi Chen maintained a Buy rating and cut the price target from $11 to $7 on Nov. 24, 2025. This analyst has an accuracy rate of 65%.
Maxim Group analyst Jason McCarthy upgraded the stock from Hold to Buy with a price target of $8 on May 20, 2025. This analyst has an accuracy rate of 44%.
Scotiabank analyst Sung Ji Nam maintained a Sector Perform rating and boosted the price target from $1 to $4 on April 2, 2025. This analyst has an accuracy rate of 57%.

Considering buying BNGO stock? Here’s what analysts think:

Photo via Shutterstock

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2620785328"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620785328\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620785328?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-20 15:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620785328","market":"us","top_or_hot":-1,"title":"Bionano Genomics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call","media":"Benzinga Earnings","content":"<html><body><p><strong><a href=\"https://laohu8.com/S/BNGO\">Bionano Genomics</a>, Inc.</strong> (NASDAQ:BNGO) will release earnings results for its fourth quarter, after the closing bell on Monday, March 23.</p>\n<p>Analysts expect the San Diego, California-based company to report a quarterly loss at $1.40 per share on revenue of $7.85 million, according to data from Benzinga Pro.</p>\n<p>On Jan. 12, Bionano Genomics said it expects fourth-quarter revenue of $7.8 million-$8.0 million and FY25 total revenue of $28.4 million-$28.6 million.</p>\n<p>Bionano Genomics shares closed at $1.12 on Thursday.</p>\n<p>Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.</p>\n<p>Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.</p>\n<ul>\n<li>HC Wainwright &amp; Co. analyst Yi Chen maintained a Buy rating and cut the price target from $11 to $7 on Nov. 24, 2025. This analyst has an accuracy rate of 65%.</li>\n<li>Maxim Group analyst Jason McCarthy upgraded the stock from Hold to Buy with a price target of $8 on May 20, 2025. This analyst has an accuracy rate of 44%.</li>\n<li>Scotiabank analyst Sung Ji Nam maintained a Sector Perform rating and boosted the price target from $1 to $4 on April 2, 2025. This analyst has an accuracy rate of 57%.</li>\n</ul>\n<p>Considering buying BNGO stock? Here’s what analysts think: </p>\n<figure><img decoding=\"async\" height=\"542\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/20025502/image-448-1024x542.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/20025502/image-448-1024x542.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/20025502/image-448-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/20025502/image-448-768x407.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/20025502/image-448.png 1212w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bionano Genomics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBionano Genomics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga Earnings </p>\n<p class=\"h-time smaller\">2026-03-20 15:54</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<html><body><p><strong><a href=\"https://laohu8.com/S/BNGO\">Bionano Genomics</a>, Inc.</strong> (NASDAQ:BNGO) will release earnings results for its fourth quarter, after the closing bell on Monday, March 23.</p>\n<p>Analysts expect the San Diego, California-based company to report a quarterly loss at $1.40 per share on revenue of $7.85 million, according to data from Benzinga Pro.</p>\n<p>On Jan. 12, Bionano Genomics said it expects fourth-quarter revenue of $7.8 million-$8.0 million and FY25 total revenue of $28.4 million-$28.6 million.</p>\n<p>Bionano Genomics shares closed at $1.12 on Thursday.</p>\n<p>Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.</p>\n<p>Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.</p>\n<ul>\n<li>HC Wainwright &amp; Co. analyst Yi Chen maintained a Buy rating and cut the price target from $11 to $7 on Nov. 24, 2025. This analyst has an accuracy rate of 65%.</li>\n<li>Maxim Group analyst Jason McCarthy upgraded the stock from Hold to Buy with a price target of $8 on May 20, 2025. This analyst has an accuracy rate of 44%.</li>\n<li>Scotiabank analyst Sung Ji Nam maintained a Sector Perform rating and boosted the price target from $1 to $4 on April 2, 2025. This analyst has an accuracy rate of 57%.</li>\n</ul>\n<p>Considering buying BNGO stock? Here’s what analysts think: </p>\n<figure><img decoding=\"async\" height=\"542\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/20025502/image-448-1024x542.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/20025502/image-448-1024x542.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/20025502/image-448-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/20025502/image-448-768x407.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/20025502/image-448.png 1212w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNGO","symbol_name":"Bionano Genomics","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/03/51372905/bionano-genomics-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call","article_id":"2620785328","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620785328","pubTimestamp":1773993250,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga Earnings","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"Bionano Genomics, Inc. (BNGO) will release Q4 earnings on March 23. Analysts expect $1.40 loss per share on $7.85M revenue. Stock closed at $1.12.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"BNGO":"Bionano Genomics"},"translate_title":"Bionano Genomics盈利迫在眉睫；这些最准确的分析师在收益看涨期权之前修改了预测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNGO":1.5},"content_text":"Bionano Genomics, Inc. (NASDAQ:BNGO) will release earnings results for its fourth quarter, after the closing bell on Monday, March 23.\nAnalysts expect the San Diego, California-based company to report a quarterly loss at $1.40 per share on revenue of $7.85 million, according to data from Benzinga Pro.\nOn Jan. 12, Bionano Genomics said it expects fourth-quarter revenue of $7.8 million-$8.0 million and FY25 total revenue of $28.4 million-$28.6 million.\nBionano Genomics shares closed at $1.12 on Thursday.\nBenzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.\nLet's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.\n\nHC Wainwright & Co. analyst Yi Chen maintained a Buy rating and cut the price target from $11 to $7 on Nov. 24, 2025. This analyst has an accuracy rate of 65%.\nMaxim Group analyst Jason McCarthy upgraded the stock from Hold to Buy with a price target of $8 on May 20, 2025. This analyst has an accuracy rate of 44%.\nScotiabank analyst Sung Ji Nam maintained a Sector Perform rating and boosted the price target from $1 to $4 on April 2, 2025. This analyst has an accuracy rate of 57%.\n\nConsidering buying BNGO stock? Here’s what analysts think: \n\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"express","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}